Skip Navigation

Nephrology Dialysis Transplantation 2007 22(Supplement 8):viii47-viii49; doi:10.1093/ndt/gfm657
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Schwenger, V.
Right arrow Articles by Zeier, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schwenger, V.
Right arrow Articles by Zeier, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Use of Erythropoietin after solid organ transplantation

Vedat Schwenger, Christian Morath and Martin Zeier

Department of Nephrology, Medical University of Heidelberg, Germany

Correspondence to: Vedat Schwenger, MD, Department of Nephrology, Medical University of Heidelberg, Germany, Im Neuenheimer Feld 162, 69120 Heidelberg, Germany. Email: vedat.schwenger{at}med.uni-heidelberg.de



  Abstract

Anaemia is common after solid organ transplantation. Although many impressive experimental data about the organoprotective properties of erythropoietin (EPO) have been reported, there are only scant clinical and experimental data about EPO use after solid organ transplantation. Since the treatment targets of anaemia in chronic kidney disease cannot be transferred to organ recipients for several reasons (rejection, immunosuppression, infection), the recommendations for optimal targets in the treatment of anaemia remain uncertain. Moreover, further studies will be necessary to clarify whether EPO administration might have haemoglobin-independent beneficial effects.

Keywords: endothelial progenitor cells; erythropoietin; organ transplantation; organoprotection


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.